Form 4: Pfizer Executive Payal Sahni Acquires Stock Appreciation Rights
SEC Form 4 Filing
Executive Vice President Payal Sahni acquired stock appreciation rights convertible to 206,569 shares of Pfizer common stock.
Summary
- Payal Sahni, an Executive Vice President at Pfizer Inc., acquired 206,569 stock appreciation rights (SARs) on March 4, 2025.
- These SARs, priced at $25.75 each, are subject to vesting requirements and will be settled in Pfizer common stock on March 4, 2030, the fifth anniversary of the grant date.
- The reporting person directly owns 206,569 derivative securities following the reported transaction.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of executive compensation. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The stock appreciation rights will be settled in shares of Pfizer common stock on March 4, 2030, subject to vesting requirements.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock appreciation rights by a top executive could be viewed positively by shareholders as it aligns the executive's interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction and acquisition of stock appreciation rights |
| 03/04/2030 | Date the stock appreciation rights become exercisable and expiration date |
| 03/06/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.